Attached files
SEGMENT INFORMATION
TECHNE CORPORATION AND SUBISIDARIES
(in thousands of $'s, except per share data)
Increase (Decrease)
Fiscal 2012 From Fiscal 2011
---------------------------------- -------------------------
First Second Third % of First Second Third
Qtr Qtr Qtr YTD Sales Qtr Qtr Qtr YTD
------ ------ ------ ------- ----- ----- ------ ----- ------
Sales 77,596 74,662 83,621 235,879 100% 9,651 6,954 7,350 23,955
Cost of sales 19,209 19,492 20,238 58,939 25% 3,859 4,165 4,297 12,321
------ ------ ------ ------- ----- ----- ------ ----- ------
Gross margin 58,387 55,170 63,383 176,940 75% 5,792 2,789 3,053 11,634
Gross margin
percentage 75.2% 73.9% 75.8% 75.0%
SG&A expense 10,773 10,651 9,899 31,323 13% 3,160 2,224 604 5,988
R&D expense 6,667 6,837 7,122 20,626 9% 48 234 825 1,107
Interest income (728) (798) (470) (1,996) (1%) 119 222 597 938
Impairment loss 0 0 3,254 3,254 1% 0 0 3,254 3,254
Other non-
operating ex.,
net 1,175 607 373 2,155 1% 918 (91) (48) 779
------ ------ ------ ------- ----- ----- ------ ----- ------
17,887 17,297 20,178 55,362 23% 4,245 2,589 5,232 12,066
------ ------ ------ ------- ----- ----- ------ ----- ------
Earnings before
income taxes 40,500 37,873 43,205 121,578 52% 1,547 200(2,179) (432)
Income taxes 12,979 12,060 11,449 36,488 16% 399 921(2,871)(1,551)
------ ------ ------ ------- ----- ----- ------ ----- ------
27,521 25,813 31,756 85,090 36% 1,148 (721) 692 1,119
====== ====== ====== ======= ===== ===== ====== ===== ======
Diluted earnings
per share 0.74 0.70 0.86 2.30
Weighted average
diluted shares
outstanding 37,170 37,028 36,930 37,043
BIOTECHNOLOGY (1)
(in thousands of $'s)
Increase (Decrease)
Fiscal 2012 From Fiscal 2011
---------------------------------- -------------------------
First Second Third % of First Second Third
Qtr Qtr Qtr YTD Sales Qtr Qtr Qtr YTD
------ ------ ------ ------- ----- ----- ------ ----- ------
Sales 72,303 69,808 78,180 220,291 100% 9,262 6,728 7,060 23,050
Cost of sales 16,465 16,887 17,444 50,796 23% 3,624 4,267 4,145 12,036
------ ------ ------ ------- ----- ----- ------ ----- ------
Gross margin 55,838 52,921 60,736 169,495 77% 5,638 2,461 2,915 11,014
Gross margin
percentage 77.2% 75.8% 77.7% 76.9%
SG&A expense 9,470 9,003 8,921 27,394 12% 2,984 2,144 995 6,123
R&D expense 6,469 6,624 6,924 20,017 9% 48 245 820 1,113
Interest income (609) (689) (387) (1,685) (1%) 53 129 484 666
Exchange loss/
gain 524 105 (164) 465 0% 1,029 18 85 1,132
------ ------ ------ ------- ----- ----- ------ ----- ------
15,854 15,043 15,294 46,191 21% 4,114 2,536 2,384 9,034
------ ------ ------ ------- ----- ----- ------ ----- ------
Pretax result 39,984 37,878 45,442 123,304 56% 1,524 (75) 531 1,980
====== ====== ====== ======= ===== ===== ====== ===== ======
(1) Includes R&D Systems' Biotechnology Division, R&D Systems Europe,
BiosPacific, R&D China, Boston Biochem and Tocris.
HEMATOLOGY
(in thousands of $'s)
Increase (Decrease)
Fiscal 2012 From Fiscal 2011
---------------------------------- -------------------------
First Second Third % of First Second Third
Qtr Qtr Qtr YTD Sales Qtr Qtr Qtr YTD
------ ------ ------ ------- ----- ----- ------ ----- ------
Sales 5,293 4,854 5,441 15,588 100% 389 226 290 905
Cost of sales 2,744 2,605 2,794 8,143 52% 235 (102) 152 285
------ ------ ------ ------- ----- ----- ------ ----- ------
Gross margin 2,549 2,249 2,647 7,445 48% 154 328 138 620
Gross margin
percentage 48.2% 46.3% 48.7% 47.8%
SG&A expense 480 400 435 1,315 9% 152 64 (3) 213
R&D expense 198 213 198 609 4% -- (11) 5 (6)
Interest income (47) (45) (23) (115) (1%) 6 21 46 73
------ ------ ------ ------- ----- ----- ------ ----- ------
631 568 610 1,809 12% 158 74 48 280
------ ------ ------ ------- ----- ----- ------ ----- ------
Pretax result 1,918 1,681 2,037 5,636 36% (4) 254 90 340
====== ====== ====== ======= ===== ===== ====== ===== ======
CORPORATE AND OTHER (2)
(in thousands of $'s)
Increase (Decrease)
Fiscal 2012 From Fiscal 2011
---------------------------- ---------------------------
First Second Third First Second Third
Qtr Qtr Qtr YTD Qtr Qtr Qtr YTD
------ ------ ------ ------- ----- ------ ----- ------
Interest income 72 64 60 196 (60) (72) (67) (199)
Rental income 134 198 150 482 11 60 36 107
------ ------ ------ ------- ----- ------ ----- ------
206 262 210 678 (49) (12) (31) (92)
SG&A expense 823 1,248 543 2,614 24 16 (388) (348)
Other-Building
expenses 587 482 545 1,614 31 (49) (41) (59)
Other-Impairment
losses 0 0 3,254 3,254 0 0 3,254 3,254
Other-Equity
Investment losses 198 218 142 558 (131) 0 (56) (187)
------ ------ ------ ------- ----- ------ ----- ------
1,608 1,948 4,484 8,040 (76) (33) 2,769 2,660
------ ------ ------ ------- ----- ------ ----- ------
Pretax result (1,402)(1,686)(4,274) (7,362) 27 21 (2,800) (2,752)
====== ====== ====== ======= ===== ====== ===== ======
(2) Unallocated corporate expenses and Techne's share of losses related
to investment in unconsolidated entities
